The ANVS-25001 trial is a Phase III clinical trial designed to examine the investigational drug buntanetap (sometimes referred to as “Posiphen”). More specifically, this drug is being tested to see whether it can help slow the progression of early Alzheimer’s disease.
What’s involved?
- Study drug will be taken daily for 18 months
- Total participation lasts about 21 months
You may qualify if you:
- Are between 55-85 years old
- Have been diagnosed with Alzheimer’s disease
- Are not currently receiving anti-amyloid therapy